AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
A phase 1/2 trial of AZD3470, Pembrolizumab in hodgkin lymphoma and non-hodgkin lymphoma, run by AstraZeneca, now recruiting.
Overview
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. is a phase 1/2 interventional study registered as NCT06137144 by AstraZeneca, with 161 participants planned, started 2024-01-23 and due to reach its primary completion in 2029-05-03. Interventions recorded: AZD3470, Pembrolizumab. Conditions listed: Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
Shares AZD3470, AstraZeneca.
- TrialA Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphom
Shares Non-Hodgkin lymphoma (all types), Hodgkin lymphoma, AstraZeneca.
- TrialSurovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Shares Non-Hodgkin lymphoma (all types), Hodgkin lymphoma, AstraZeneca.
- TrialStudy of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Shares Non-Hodgkin lymphoma (all types), Hodgkin lymphoma, AstraZeneca.
- TrialT-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- TrialA Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Ly
- TrialA Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients
- TrialA Study of Carmustine With and Without Ethanol in Subjects With Lymphoma